Hung M J, Oremek G M
Depatment of Laboratory Medicine, Internal Medicine, Hospital of the Johann Wolfgang Goethe University, Frankfurt am Main, Germany.
Eur J Gynaecol Oncol. 2011;32(6):615-8.
BACKGROUND/AIMS: The aim of the study was to test the bone resorption marker TRAcP 5b regarding its suitability for detection of bone metastases in breast cancer patients.
Serum samples from a total of 101 patients with histologically proven breast cancer and from 100 healthy probands were analyzed. The patients were divided into three groups: eight patients without osseous involvement, 65 patients with untreated bone metastases, 28 patients whose bone metastases were treated with bisphosphonate therapy.
The TRAcP 5b concentration was significantly higher in breast cancer patients compared to healthy probands. It was not possible to demonstrate a statistically significant difference in the TRAcP 5b concentration if osseous metastases in breast cancer patients were present or not.
Our research cannot support the claim that TRAcP 5b could be useful as a diagnostic tool for the detection of bone metastases in patients with breast cancer.
背景/目的：本研究旨在检测骨吸收标志物抗酒石酸酸性磷酸酶5b（TRAcP 5b）对乳腺癌患者骨转移的检测适用性。
分析了101例经组织学证实的乳腺癌患者及100例健康对照者的血清样本。患者分为三组：8例无骨转移患者，65例未经治疗的骨转移患者，28例接受双膦酸盐治疗的骨转移患者。
与健康对照者相比，乳腺癌患者的TRAcP 5b浓度显著更高。乳腺癌患者有无骨转移时，TRAcP 5b浓度无统计学差异。
我们的研究不支持TRAcP 5b可作为乳腺癌患者骨转移诊断工具的说法。
Zotero 插件